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doi:10.1016/j.jfma.2011.09.028Background/Purpose: Community-acquired pneumonia (CAP) and healthcare-associated pneu-
monia (HCAP) may be caused by potential antimicrobial drug-resistant (PADR) microbes. The
aims of this study were to evaluate the incidences and risk factors associated with PADR
microbes observed in patients with pneumonia occurring outside the hospital setting in Taiwan.
Methods: We conducted a retrospective study of patients with CAP or HCAP admitted to six
medical centers in the northern, central, and southern regions of Taiwan in 2007. The pathogens
were evaluated by microbiological specimens within 72 hours after admission. The patients’of Internal Medicine, National Taiwan University Hospital, Number 7, Chung-Shan South Road, Taipei
du.tw (C.-J. Yu).
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Pseudomonascomorbidities, pathogens, and outcomes were evaluated. The risk factors of PADR microbes
were identified by logistic regression analysis.
Results: The enrolled patients exhibited HCAP (nZ 713) and CAP (nZ 933). The pathogens
associated with HCAP (nZ 383) and CAP (nZ 441) included Pseudomonas spp. (29%vs. 10%,
p< 0.001), Klebsiella spp. (24% vs. 25%, pZ 0.250), Escherichia coli (6% vs. 8%, pZ 0.369),Hae-
mophilus influnezae (3% vs. 7%, pZ 0.041), Streptococcus pneumoniae (2% vs. 6%, pZ 0.003)
and methicillin-resistant Staphylococcus aureus (MRSA) (8% vs. 4%, pZ 0.008). The core patho-
gens of CAP and HCAP differed among the three regions of Taiwan. PADR microbes, including
Pseudomonas spp. (nZ 191), Acinetobacter spp. (nZ 41), MRSA (nZ 49) and cefotaxime- or
ceftazidime-resistant Enterbacteriaceae (nZ 25), were isolated from 13% of patients with
CAP and 23% of patients with HCAP. Previous hospitalization, and neoplastic and neurological
diseases were significant risk factors for acquiring PADR microbes.
Conclusion: PADR microbes were common in patients with HCAP and CAP in Taiwan. Broad-
spectrum antibiotics targeting PADR microbes should be administered to patients who have
undergone previous hospitalization and who exhibit neurological disorders and/or
malignancies.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Pneumonia occurring in patients undergoing regular dial-
ysis, infusion therapy, and immunosuppressive therapy or in
patients in long-term care facilities has been classified
as healthcare-associated pneumonia (HCAP).1,2 These
patients are at risk of acquiring microorganisms resistant to
multiple drugs. However, in prior studies, the core patho-
gens that were demonstrated to be associated with HCAP
vary markedly.2e6 Potential antimicrobial drug-resistant
(PADR) microbes are confirmed only in 22e29% cases of
HCAP in studies conducted in Japan and Korea.3,6 Pseudo-
monas aeruginosa was detected in 1.6% and 25.5% of
patients with HCAP in Spain and the United States,
respectively.4,5 A comprehensive review of HCAP concluded
that HCAP is a heterogeneous disease and that not all HCAP
patients require a broad-spectrum antibiotic for adequate
empiric therapy.7 Furthermore, PADR microbes are exhibi-
ted by 6e13% of patients with community-acquired pneu-
monia (CAP).3,6 HCAP appears to be neither a sensitive nor
a specific diagnosis of the pneumonia caused by PADR
microbes. Therefore, improved definitions of the risk
factors for acquiring PADR microbes are needed for patients
with HCAP and CAP.
In this study, we provided an overview of HCAP under the
healthcare system of Taiwan, and retrospectively
compared the clinical presentations, microbiology, and
outcomes associated with CAP and HCAP. The risk factors
associated with both CAP and HCAP caused by PADR
microbes were identified, and a risk-adapted approach was
constructed for managing pneumonia occurring outside the
hospital setting.Materials and methods
Participants
This study was conducted retrospectively at six medical
centers, including Taipei Veterans General Hospital,National Taiwan University Hospital, Taichung Veterans
General Hospital, China Medical University Hospital,
National Cheng Kung University Hospital, and Kaohsiung
Chang Gung Memorial Hospital. The records of all of the
patients with pneumonia who were discharged from these
centers in 2007 were reviewed. This study was approved by
the Institutional Review Board of each medical center, and
the informed consent of the patients was waived.Criteria of CAP and HCAP
The patients in the study presented with pneumonia that
was diagnosed within 48 hours after hospitalization,
according to the criteria outlined in the study by Lau-
derdale et al.8 Patients were excluded from the study if
they exhibited one of the following characteristics: (1) age
< 18 years; (2) pneumonia developing 2 days after admis-
sion or less than 14 days after the last hospitalization; (3)
lung cancer with obstructive pneumonia; or (4) HIV-positive
status with a CD4þ count < 200.
Patients were classified as displaying HCAP if they
satisfied at least one of the following criteria before
admission: (1) receiving regular dialysis at an outpatient
clinic; (2) receiving radiation therapy or chemotherapy at
an outpatient clinic; (3) undergoing a repeated hospitali-
zation within 90 days prior to the episode of pneumonia in
question; or (4) residing in a nursing home. Enrolled
patients in the study who did not fulfill the above four
criteria for HCAP were classified as displaying CAP.Comorbidities and clinical presentations
The study’s comorbidities and clinical presentations were
defined according to the standards employed in the study by
Fineet al andHsu et al.9,10 In addition, patientswith diabetes
mellitus were defined as those treated with oral antidia-
betics or insulin injections. Autoimmune diseases included
all collagen vascular diseases. Immunocompromisedpatients
were defined as those under immunosuppressive therapy.
Drug resistant microbes of CAP and HCAP 33Finally, the pneumonia severity index (PSI) was calculated
according to the studies by Fine et al.9
Microbiology
The specimens obtained within 72 hours after admission,
including sputum, tracheal aspirates, bronchoalveolar
lavage fluid, pleural effusions, blood, and urine for
Legionella pneumophila or the Streptococcus pneumoniae
antigen test, were employed for etiological evaluations. In
addition, paired serology tests were utilized for microbio-
logical evaluations. The pathogens associated with CAP and
HCAP were defined according to the principles proposed by
Lauderdale et al.8
The antimicrobial susceptibility of those microbes was
determined by the disk diffusion method.11 Only non-
duplicate isolates were included in calculations deter-
mining the susceptibility rates. Microbes exhibiting both
intermediate and high levels of resistance to antibiotics
were regarded as resistant. PADR microbes included Pseu-
domonas spp. Acinetobacter spp., MRSA and cefotaxime- or
ceftazidime-resistant Enterbacteriaceae.12
Assessment of treatment
Empirical antibiotics were administered during the first 48
hours after admission and were determined to be appro-
priate if they demonstrated activity against the identified
pathogens. Microbiological and clinical responses to
empirical antibiotics were evaluated at 7 days after
admission. Microbiological eradication or persistence was
defined according to the absence or presence of the orig-
inal pathogens in cultures obtained from the original site of
infection. Successful clinical responses were assessed by
the principal investigators at each center based on the
improvement of pretreatment signs and symptoms and the
absence of the requirement for additional antibiotics.
Patients who exhibited a “failure of clinical response”
included those who displayed persistent signs and symp-
toms and required another course of antibiotic therapy.
Statistics
Continuous variables were expressed as mean SD.
Student’s t-test and Chi-square test were employed to
compare the variables between CAP and HCAP. Backward
stepwise logistic regression analysis was employed to
identify the risk factors associated with specific microbes.
The analyses were performed with SPSS software for MS
Windows with significance defined as p< 0.05.
Results
Clinical presentations of patients with CAP or HCAP
A total of 1646 patients were classified as either patients
with CAP (nZ 933) or patients with HCAP (nZ 713). The
comorbidities associated with HCAP were more common
than those associated with CAP (Table 1). HCAP was more
severe than CAP, as indicated by PSI, acute respiratoryfailure (ARF), shock, admission to the intensive care unit,
and mortality (Table 1). Of the 658 patients exhibiting
identified pathogens, the mortality rate was significantly
lower for the patients receiving appropriate antibiotics
(14.2%) than for the patients receiving inappropriate anti-
biotics (24.7%). Based on the clinical response and
mortality rates, the patients with CAP were observed to
respond better to treatment than did the patients with
HCAP (Table 1).Distribution of pathogens between CAP and HCAP
In this study, 1356 respiratory specimens were sampled for
bacteria cultures, 1262 blood cultures were taken, and 565
specimens were sampled for tuberculosis cultures. Of 63
Legionella urine antigen tests, none was positive. Of 65
pneumococcal urine-antigen tests, nine were positive. The
serological tests for atypical pathogens, for example,
Mycoplasma pneumoniae (nZ 166), Legionella (nZ 119),
and Chlamydophila pneumoniae (nZ 68), were conducted
less frequently.The etiological agents were diagnosed in
362 (38.8%) patients presenting CAP and 296 (41.5%)
patients exhibiting HCAP.
A total of 824 probable or definite microbes were
isolated from patients displaying CAP (nZ 441) or HCAP
(nZ 383). Pseudomonas spp., Enterbacter spp., Steno-
trophomonas maltophilia, and MRSA were significantly
more common in patients exhibiting HCAP. Haemophilus
influenzae and Streptococcus pneumoniae were more
common in patients presenting CAP than in patients
displaying HCAP (Table 2). The antibiotic sensitivity rates
of Pseudomonas spp. obtained from patients exhibiting
CAP and from patients displaying HCAP were similar
(Fig. 1A), whereas those of Klebsiella spp. and Escher-
ichia coli were significantly lower in patients presenting
HCAP than in patients exhibiting CAP (Fig. 1, panels B and
C). Atypical pathogens were rarely observed in the
present study.Pneumonia induced by PADR microbes
The PADR microbes included Pseudomonas spp. (nZ 191),
Acinetobacter spp. (nZ 41), MRSA (nZ 49), and cefo-
taxime- or ceftazidime-resistant Enterbacteriaceae
(nZ 25). Thirteen percent of patients exhibiting CAP
(nZ 123) and 23% of patients displaying HCAP (nZ 162)
acquired PADR microbes. Overall, 43% of patients pre-
senting culture-positive pneumonia acquired PADR
microbes. However, the utilization of HCAP as a screening
test for PADR microbes indicated that the test’s sensitivity
and specificity were only 54.7% and 66.0%, respectively.
Inappropriate empiric antibiotics were administered to
38.9% and 12.6% of the patients with and without PADR
microbes, respectively (p< 0.001). The percentages of
microbiological persistence (20.6% vs. 12.3%, pZ 0.004),
clinical failure (36.2% vs. 28.1%, pZ 0.022), and mortality
(24.9% vs. 14.2%, p< 0.001) were also significantly
elevated in the culture-positive patients exhibiting PADR
microbes compared with the patients not displaying PADR
microbes.
Table 1 Various features of patients exhibiting community-acquired pneumonia (CAP) or healthcare-associated pneumonia
(HCAP).
Variables Total (nZ 1646) CAP (nZ 933) HCAP (nZ 713) p
Male/female 1181/465 674/259 507/ 206 0.336
Age 72 16 72 17 73 15 0.577
Regular dialysis 72 (10.8)
Radiotherapy and chemotherapy 142 (19.9)
Repeated admission 412 (57.8)
Resident of nursing home 207 (29.0)
Comorbidities
Neoplastic disease 330 (20.1) 78 (8.4) 252 (35.3) 0.000
Liver disease 86 (5.2) 41 (4.4) 45 (6.3) 0.054
Cardiovascular disease 609 (37.0) 361 (38.7) 248 (34.8) 0.055
Neurological disorders 467 (28.4) 206 (22.1) 261 (36.6) 0.000
Renal disorder 200 (12.2) 69 (7.4) 131 (18.4) 0.000
Pulmonary disease 611 (37.2) 330 (35.4) 281 (39.4) 0.055
Diabetes mellitus 444 (27.0) 236 (25.3) 208 (29.2) 0.047
Immunocompromised status 67 (4.1) 15 (1.6) 52 (7.3) 0.000
Autoimmune disease 42 (2.6) 21 (2.3) 21 (2.9). 0.236
PSI 133 35 126 32 142 32 <0.001
Acute respiratory failure 385 (23.6) 149 (16.2) 236 (33.3) <0.001
Septic shock 235 (14.4) 95 (10.3) 140 (19.7) <0.001
Intensive care unit admission 438 (26.6) 187 (20.0) 251 (35.2) <0.001
Antibiotic therapy for culture positive cases (nZ 658)a
Appropriate 358 (54.4) 193 (53.3) 165 (55.7) 0.582
Inappropriate 158 (24.0) 78 (21.5) 80 (27.0) 0.119
Microbiological eradication for culture positive cases (nZ 612)a
Eradication 122 (19.9) 73 (20.3) 49 (19.4) 0.838
Persistence 97 (15.8) 47 (13.1) 50 (19.8) 0.025
Clinical response (nZ1483)a
Success 982 (66.2) 674 (72.7) 308 (55.4) <0.001
Failure 420 (28.3) 218 (23.5) 202 (36.3) <0.001
Length of hospitalization (day) 19.5 22.5 17.7 18.6 22.0 24.6 <0.001
Length of ICU (day) 18.3 19.0 19.9 22.8 17.2 15.6 0.145
Mortality 303 (18.4) 112 (12.0) 191 (26.8) <0.001
PSIZpneumonia severity index.
a indeterminate cases were not shown.
34 C.-L. Wu et al.Risk factors associated with PADR organisms,
nonresistant Enterbacteraciae or Streptococcus
spp./Haemophillus influenzae
As determined by logistic regression analysis, independent
risk factors for the acquisition of PADR microbes by patients
exhibiting CAP or HCAP included repeated hospital admis-
sions, malignancies, and neurological disorders. Residing at
a nursing home was not a significant factor associated with
PADR microbes. The patients exhibiting neoplasms and
currently under chemotherapy or radiotherapy were even
less frequently infected with PADR microbes (Table 3). Up
to 89% of culture-positive patients simultaneously under-
going repeated admission and exhibiting neurological
disorders and malignancies simultaneously acquired PADR
microbes.
A total of 290 microbes were Enterbacteriaceae. Only 25
(8.6%) of them were resistant to cefotaxime or ceftazidime.
The factors associated with pneumonia induced by nonre-
sistant Enterbacteriaceae were different from those
induced by PADR microbes, with the exception of repeatedadmission (Table 3). Furthermore, repeated admission was
a negative independent factor for predicting the pneu-
monia induced by Streptococcus spp. (nZ 62) and/or
Haemophilus influenzae (nZ 44). Based on the risk factors
associated with specific pathogens (Table 3), an algorithm
was proposed for managing pneumonia cases occurring
outside the hospital setting (Fig. 2).
Core pathogens of CAP and HCAP differed among the
northern, central, and southern regions of Taiwan and
among different countries.
The features of CAP and HCAP patients from the three
regions of Taiwan are shown in Table 4. The comorbidities
were different among the three regions. Pseudomonas spp.
was dominant in the north. Klebsiella spp. was less isolated
in the south. The incidence of Acinetobacter spp. seemed
higher in the south than in the other regions. S. pneumo-
niae were more common in both CAP and HCAP of central
Taiwan. Furthermore, we summarized the global published
studies of HCAP in Table 5, which suggests the heteroge-
neity of HCAP too. Klebsiella spp. was common in Asia,
especially in Taiwan. The incidences of MRSA and
Table 2 Pathogen distribution of community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP).
Variables Total (nZ 824) CAP (nZ 441) HCAP (nZ 383) p*
Gram-negative pathogens
Klebsiella spp. 201 (24.4) 109 (24.7) 92 (24.0) 0.250
Pseudomonas spp. 191 (23.1) 79 (10.2) 112 (29.2) <0.001
Escherichia coli 55 (6.7) 33 (7.5) 22 (5.7) 0.359
Haemophilus influenzae 44 (5.3) 31 (7.0) 13 (3.3) 0.041
Acinetobacter spp. 41 (5.0) 23 (5.2) 18 (4.7) 0.530
Enterbacter spp. 27 (3.2) 9 (2.0) 18 (4.7) 0.012
Serratia marcescens 16 (1.9) 6 (1.4) 10 (2.6) 0.097
Proteus mirabilis 13 (1.6) 4 (0.9) 9 (2.3) 0.054
Stenotrophmonas maltophilia 10 (1.2) 1 (0.2) 9 (2.3) 0.003
Citrobacter spp. 2 (0.2) 0 (0.0) 2 (0.5) 0.187
Moraxella catarrhalis 3 (0.3) 3 (0.7) 0 (0.0) 0.182
Others 10 (1.2) 5 (1.1) 5 (1.3) 0.452
Gram-positive pathogens
MRSA 49 (5.9) 19 (4.3) 30 (7.8) 0.008
MSSA 35 (4.4) 24 (5.4) 11 (2.9) 0.102
Streptococcus pneumoniae 32 (3.9) 26 (5.9) 6 (1.6) 0.003
Other Streptococcus spp. 30 (3.6) 20 (4.5) 10 (2.6) 0.177
Entercoccus spp. 9 (1.1) 6 (1.4) 3 (0.8) 0.401
Others 23 (2.8) 15 (3.4) 8 (2.1) 0.270
Others
Legionella spp. 8 (1.0) 7 (1.6) 1 (0.3) 0.075
Mycoplasma pneumoniae 8 (1.0) 8 (1.8) 0 (0.0) 0.270
Chlamydophilia pneumoniae 4 (0.5) 4 (0.9) 0 (0.0) 0.103
Mycobacterium tuberculosis 13 (1.6) 9 (2.0) 4 (1.0) 0.266
*indicates the comparison between CAP and HCAP.
MRSAZ methicillin-resistant Staphylococcus aureus; MSSAZ methicillin-sensitive Staphylococcus aureus.
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Taiwan, respectively. However, the incidence of S. pneu-
moniae might be underestimated in Taiwan.Discussion
The distribution of pathogens was different between
patients exhibiting CAP and patients displaying HCAP.
However, 13% of patients exhibiting CAP and 23% of patients
presenting HCAP acquired PADR microbes. Repeated
admission was the most important risk factor associated
with acquiring PADR microbes. If the patients had been
admitted before, neoplastic and neurological disorders
were important factors in determining empiric antibiotics
for PADR microbes or nonresistant Enterbacteriaceae.
At first, we had to take the healthcare systems into
account in interpreting the results. In Taiwan, long-term
care facilities comprise care organizations, nursing organi-
zations, and long-term nursing organizations. The boundary
between hospitals and the community no longer seems to
be secure because of daytime hospital care, hospital-based
nursing homes, and the high accessibility of healthcare
resources that enable patients to visit the hospital without
a referral. Therefore, the community is at risk of con-
tracting drug-resistant microorganisms.
The enrolled patients exhibited severe symptoms, as
87.7% were graded as PSI class IV and V. The percentages of
ARF in this study’s CAP and HCAP cases were 16.2% and
33.3%, respectively, which were higher than those reportedby the studies by Kollef et al and Carralata et al.2,5,6 They
were similar to those of the report by Micek et al.4 (Table
5). The mortality rates displayed by patients with CAP
(12.0%) and by patients with HCAP (26.8%) were also higher
than those described by previous reports (CAP: 4.3e10.0%;
HCAP: 10.3e24.6%)2e4,6 (Table 5). Employing a similar
procedure to that of previous studies,4,6,13 we enrolled
patients who had received radiotherapy and chemotherapy
because of their regular visits to hospital-based clinics.
Therefore, 35.3% of the patients exhibited malignancies.
Taiwan healthcare systems and the severity and comor-
bidities of the patients exhibiting CAP or HCAP should be
considered when the data are interpreted.
All of the studies investigating HCAP2e4,6 except for
two5,13 were retrospective. All of the studies indicated that
S. pneumoniae was the primary pathogen in patients
exhibiting both CAP and HCAP. However, only 7.2% of
culture positive cases of CAP and 2.0 % of culture positive
cases of HCAP in this study were caused by S. pneumoniae.
There are three possible reasons that may explain the low
incidence of S. pneumoniae. First, the pneumococcal urine
antigen was underutilized. Second, all six of the sites were
tertiary medical centers. Those patients may be referred to
the medical centers selectively. Third, elevated disease
severity, frequent underlying malignancy, and repeated
hospital admission may have led to the colonization of
gram-negative bacilli.
The incidence of CAP resulting from Pseudomonas spp.
was lower (1.7% to 17.1%) than that of HCAP (5.7% to 25.5%)
in retrospective studies of CAP and HCAP.2e4,6 Two recent
Figure 1 Antibiotic susceptibilities of Pseudomonas spp. (A), Klebsiella spp. (B), and E. coli (C) were compared between CAP and
HCAP. *Significant difference between the linked groups by a Chi-square test with p< 0.05.
36 C.-L. Wu et al.European prospective studies highlighted the low incidence
of CAP resulting from Pseudomonas spp. (0.4% to 0.5%).5,14
However, the incidence of CAP induced by Pseudomonas
spp. increased to 15.5% in elderly patients15 and 6.7% in
Asia CAP.16 In this study, Pseudomonas spp. accounted foras much as 29.2% and 10.2% of HCAP- and CAP-associated
pathogens, respectively, probably because the patients
were elderly and exhibited severe disease. The validity of
the microbiological data may also be questioned because of
the retrospective study design. However, we could not






H. influenzae OR (95% CI)
Regular dialysis
Radiation or chemotherapy 0.475 (0.268e0.841)*
Hospitalization  90 days 1.964 (1.456e2.633)* 1.404 (1.045e1.888)* 0.372 (0.196e0.716)*
Resident of nursing home
Age  75 years
Neoplastic disorders 1.835 (1.276e2.633)*
Liver diseases 1.629 (0.963e2.756)
Neurologic disorders 1.625 (1.220e2.165)* 0.595 (0.351e1.007)
Renal disorders




*Logistic regression with p< 0.05.
PADRZ potential antimicrobial drug-resistant; ORZ odd ratio; CIZ confidence interval.
Drug resistant microbes of CAP and HCAP 37ignore the markedly significant predominance of Pseudo-
monas spp. in the patients exhibiting HCAP and CAP.
Klebsiella spp. was the leadingmicrobe of CAP, and it was
distributed equally in CAP and HCAP cases, probably due to
the high prevalence of Klebsiella spp. in community-
acquired and nosocomial infection. Klebsiella spp. has
been reported to be the common core pathogen associated
with cases of CAP, 8,16 severe CAP,17 acute exacerbation of
COPD,18 andempyema thoracis19 in Taiwan.Klebsiella spp. is
also themicrobemost commonly observed in the nosocomial
setting in Taiwan.20e22 Therefore, Klebsiella spp. was
described in this report as the leading microbe associated
with CAP and most commonly isolated in HCAP. However,
94.8% of HCAP cases induced by Enterbacteriaceae wereFigure 2 The algorithm for identifying the pneumonia caused by
factors. The factors marked with (?) were borderline significant.nonresistant strains, especially in those patients undergoing
repeated hospital admissions but not exhibiting neurological
disorders and malignancies (Table 3). These cases did
not require broad-spectrum empiric anti-Pseudomonas
antibiotics.
In this retrospectively designed study,we could not define
whether Enterbacteriaceae produced extended-spectrum
b-lactamase (ESBL). We regarded cefotaxime- and
ceftazidime-resistant Enterbacteriaceae to be potential
ESBL-producing bacteria. Therefore, PADR microbes were
defined accordingly.
Repeated admissions represented a significant indepen-
dent risk factor for acquiring PADR microbes, in keeping
with the results of previous studies, but the other riskspecific microbes was proposed based on the independent risk
Table 4 Various features of community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP) among
patients from north, central, and south Taiwan.
Type of infection CAP p HCAP p
Regions of Taiwan North Central South North Central South
Case number (n) 618 171 144 278 208 227
Repeated admission (%) 67.6 61.1 42.7 <0.001
Neoplastic diseases (%) 9.4 1.8 11.9 0.002 36.3* 46.2* 24.2* <0.001
Neurological disorders (%) 23.0 16.4 25.0 0.120 39.9* 21.2 46.7* <0.001
Culture-positive cases (n) (%) 236 (38.2) 60 (35.1) 66 (45.8) 0.129 165 (59.4)* 67 (32.2) 64 (28.2)* <0.001
Common pathogens among culture-positive cases
Klebsiella spp. (%) 37.7 18.3 13.6 <0.001 35.2 34.3* 17.2 0.025
Pseudomonas spp. (%) 23.7 16.7 19.7 0.447 44.8* 25.4 32.8 0.014
Escherichia coli (%) 8.9 6.7 12.1 0.558 6.7 11.9 4.7 0.244
Haemophilus influenza (%) 8.1 11.7 7.6 0.638 3.6 0* 10.9 0.007
Acinetobacter spp. (%) 4.7 5.0 13.6 0.027 6.1 3.0 9.4 0.310
MRSA (%) 5.9 1.7 6.1 0.395 9.1 10.4* 12.5 0.742
MSSA (%) 6.4 8.3 6.1 0.842 4.8 1.5 3.1 0.454
Streptococcus pneumoniae (%) 5.5 18.3 3.0 0.001 1.2* 6.0* 0.0 0.028
PADR microbes (%) 35.2 23.3 39.4 0.132 58.2* 46.3* 54.7* 0.255
p: indicates the significant difference among the regions of Taiwan in patients with CAP or HCAP (Chi-square test).
*Indicates the features of HCAP were significantly different from those of CAP in each region of Taiwan (Chi-square test, p< 0.05).
PADRZ potential antimicrobial drug-resistant.
38 C.-L. Wu et al.factors previously associated with HCAP were not sup-
ported in this study.14,23 These results support the notion
that HCAP is heterogeneous7 and that empiric antibiotics
for PADR microbes should not be given simply according to
the categories of CAP and HCAP. Functional disability is
a risk factor of multiple drug-resistant organisms in cases of
elderly patients with severe pneumonia.24 In Taiwan, the
functional disability of residents in nursing homes varied
widely from ambulant to bed-ridden patients. These vari-
ations in functional status may compromise the power of
nursing home residency as a risk factor in predicting theTable 5 Comparison of the features of community-acquired pne





CAP HCAP CAP HCAP
Age 72 17 73 15 57 17 60
ICU admission (%) 20.0 35.2 37.0 48.7
Mechanical ventilator (%) 16.2 33.3 31.3 44.5
Length of hospitalization 18 19 22 25 ND ND
Mortality (%) 12.0 26.8 9.1 24.6
Neoplastic disease (%) 8.4 35.3 ND ND
Neurological disease (%) 22.1 36.6 ND ND
Etiology diagnosis (%) 38.8 41.5 100 100
Pseudomonas spp. (%)b 21.8 37.8 4.8 25.5
Klebsiellae spp. (%)b 30.1 31.1 3.4 6.5
S. pneumoniae (%)b 7.2 2.0 40.9 10.4
MRSA (%)b 5.2 10.1 12.0 30.6
Atypical pathogens (%)b 4.7 0.3 ND ND
MRSAZmethicillin-resistant Staphylococcus aureus; NDZ no data.
a Median.
b The frequencies of the pathogens among the culture-positive caseacquisition of PADR microbes. Furthermore, neurological
disorders, usually associated with functional disability,
were a significant independent risk factor for PADR
microbes. Additionally, neoplastic disorders were one of
the significant independent risk factors for acquiring PADR
microbes. However, those patients exhibiting malignancies
and currently under chemotherapy or radiotherapy were
less likely to be infected by PADR microbes, probably
because they had strong functional statuses and they were
able to visit outpatient clinics. We could stratify the








CAP HCAP CAP HCAP CAP HCAP
19 64 17 70 15 70 17 81 10 67a 65a
8.7 6.3 ND ND 16.0 24.2
4.7 3.2 ND ND 9.8 13.7
8a 9a ND ND 8 13
4.3 10.3 7.4 21.3 7.4 19.2
4.7 15.1 14.8 14.2 20.9 64.8
11.8 30.1 20.0 5.5 5.5 41.8
56.1 67.5 47.4 54.6 28.2 35.7
0.5 12.5 3.7 10.3 4.3 13.8
0.1 0 3.7 13.0 8.7 20.0
33.9 27.8 40.4 24.7 60.8 38.5
0 2.4 1.8 6.5 2.1 7.7
3.7 1.6 14.7 1.2 ND ND
s.
Drug resistant microbes of CAP and HCAP 39then consider antibiotic treatment of PADR microbes for
those patients with neurological disorders or malignancies
(Fig. 2). Further prospective studies are required to vali-
date the algorithm.
Limitations of the study
First, this study was retrospective, which compromised
the study of core pathogens. The previous antibiotic
exposure could not be traced well. Second, most of the
pathogens were defined based on positive culture of
sputum or endotracheal aspirates. Few cases received
invasive diagnosis, for example bronchoalveolar lavage, to
identify the pathogens. Colonization and infection could
not be separated from each other, which might have
compromised the validity of the data. Third, the process
for admitting patients to the six medical centers may
be highly selective. Fourth, the urine antigen and
serial serological tests were underutilized. Therefore,
researchers should be careful when extrapolating these
data to district hospitals.Conclusions
The distribution of the pathogens of CAP and HCAP differed
not only among different countries but also among the
three regions of Taiwan. We conducted the multicenter
study to identify the risk factors associated with pneumonia
induced by PADR microbes in Taiwan. PADR microbes were
not only isolated from the patients with HCAP but also from
patients exhibiting CAP. Empiric antibiotics for treating
pneumonia occurring outside the hospital setting should not
be administered based only on the categories of CAP and
HCAP. Broad-spectrum antibiotics for PADR microbes were
recommended to patients with histories of previous
hospital admissions, as well as neurological disorders or
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